Figure 2From: Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanomaCharacterization of the patients’ IFN-DCs used in the clinical trial. IFN-DCs were checked for viability and recovery and capability of antigen uptake(a), and characterized for typical differentiation and activation markers (b) as well as class I-II and costimulation molecules (c).Back to article page